Overview Dividends

(EW) Edwards Lifesciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082

Valve Replacement, Valve Repair, Surgical Valves

EW EPS (Earnings per Share)

EPS Growth (3Y CAGR): 1.68%
EPS Trend (3Y Correlation): 28.7%

EW Revenue

Revenue Growth (3Y CAGR): 5.28%
Revenue Trend (3Y Correlation): 61.4%

Description: EW Edwards Lifesciences September 29, 2025

Edwards Lifesciences (NYSE:EW) develops and sells minimally invasive cardiovascular devices, including the transcatheter aortic valve replacement (TAVR) SAPIEN system, the mitral/tricuspid repair platforms PASCAL PRECISION and Cardioband, and a suite of surgical structural-heart products under the INSPIRIS brand such as RESILIA tissue valves and the KONECT conduit. The firm markets its portfolio worldwide through a direct sales force and independent distributors, and has been operating since 1958 from its Irvine, California headquarters.

Key recent metrics: FY 2023 revenue reached approximately $5.2 billion, driven by a 12 % year-over-year increase in TAVR sales, which now represent roughly 45 % of the U.S. TAVR market share. The company’s pipeline includes next-generation RESILIA tissue technologies that aim to extend valve durability, a critical factor as the aging global population (projected to exceed 1.5 billion people over 65 by 2030) fuels demand for less invasive cardiac interventions. A material economic driver is Medicare’s evolving reimbursement policy for TAVR, which can materially affect pricing power and adoption rates.

For a deeper, data-rich analysis of EW’s valuation dynamics, consider exploring the detailed metrics and scenario models available on ValueRay.

EW Stock Overview

Market Cap in USD	48,406m
Sub-Industry	Health Care Equipment
IPO / Inception	2000-03-27

EW Stock Ratings

Growth Rating	26.3%
Fundamental	68.3%
Dividend Rating	-
Return 12m vs S&P 500	11.1%
Analyst Rating	3.69 of 5

EW Dividends

Currently no dividends paid

EW Growth Ratios

Growth Correlation 3m	-4.3%
Growth Correlation 12m	73.3%
Growth Correlation 5y	-64.7%
CAGR 5y	3.80%
CAGR/Max DD 3y (Calmar Ratio)	0.10
CAGR/Mean DD 3y (Pain Ratio)	0.24
Sharpe Ratio 12m	0.09
Alpha	6.64
Beta	1.047
Volatility	27.77%
Current Volume	2624.7k
Average Volume 20d	4179k
Stop Loss	80.8 (-3.1%)
Signal	1.10

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (1.36b TTM) > 0 and > 6% of Revenue (6% = 353.0m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 3.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 81.24% (prev 89.64%; Δ -8.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 1.20b <= Net Income 1.36b (YES >=105%, WARN >=100%)

Net Debt (-2.35b) to EBITDA (1.66b) ratio: -1.41 <= 3.0 (WARN <= 3.5)

Current Ratio 4.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (585.7m) change vs 12m ago -2.07% (target <= -2.0% for YES)

Gross Margin 78.22% (prev 79.37%; Δ -1.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.21% (prev 41.14%; Δ 4.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 62.48 (EBITDA TTM 1.66b / Interest Expense TTM 19.8m) >= 6 (WARN >= 3)

Altman Z'' 11.09

(A) 0.37 = (Total Current Assets 6.29b - Total Current Liabilities 1.51b) / Total Assets 13.06b

(B) 1.01 = Retained Earnings (Balance) 13.17b / Total Assets 13.06b

warn (B) unusual magnitude: 1.01 — check mapping/units

(D) 4.54 = Book Value of Equity 13.58b / Total Liabilities 2.99b

Total Rating: 11.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.34

1. Piotroski 6.0pt = 1.0

2. FCF Yield 2.19% = 1.10

3. FCF Margin 17.16% = 4.29

4. Debt/Equity 0.07 = 2.50

5. Debt/Ebitda -1.41 = 2.50

6. ROIC - WACC (= -0.17)% = -0.22

7. RoE 13.57% = 1.13

8. Rev. Trend 61.40% = 4.60

9. EPS Trend 28.69% = 1.43

What is the price of EW shares?

As of November 09, 2025, the stock is trading at USD 83.39 with a total of 2,624,742 shares traded.
Over the past week, the price has changed by +1.14%, over one month by +8.69%, over three months by +7.01% and over the past year by +26.66%.

Is Edwards Lifesciences a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 68.34 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EW is around 75.39 USD . This means that EW is currently overvalued and has a potential downside of -9.59%.

Is EW a buy, sell or hold?

Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.

Strong Buy: 10
Buy: 4
Hold: 17
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the EW price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	92.5	10.9%
Analysts Target Price	92.5	10.9%
ValueRay Target Price	85	1.9%

EW Fundamental Data Overview November 02, 2025

Market Cap USD = 48.41b (48.41b USD * 1.0 USD.USD)
P/E Trailing = 34.4979
P/E Forward = 27.8552
P/S = 8.5146
P/B = 4.2674
P/EG = 4.1293
Beta = 1.047
Revenue TTM = 5.88b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.66b USD
Long Term Debt = 597.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 23.4m USD (from shortTermDebt, last fiscal year)
Debt = 700.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.35b USD (from netDebt column, last fiscal year)
Enterprise Value = 46.06b USD (48.41b + Debt 700.0m - CCE 3.05b)
Interest Coverage Ratio = 62.48 (Ebit TTM 1.24b / Interest Expense TTM 19.8m)
FCF Yield = 2.19% (FCF TTM 1.01b / Enterprise Value 46.06b)
FCF Margin = 17.16% (FCF TTM 1.01b / Revenue TTM 5.88b)
Net Margin = 23.19% (Net Income TTM 1.36b / Revenue TTM 5.88b)
Gross Margin = 78.22% ((Revenue TTM 5.88b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 77.77% (prev 77.64%)
Tobins Q-Ratio = 3.53 (Enterprise Value 46.06b / Total Assets 13.06b)
Interest Expense / Debt = 2.83% (Interest Expense 19.8m / Debt 700.0m)
Taxrate = 16.10% (56.1m / 348.4m)
NOPAT = 1.04b (EBIT 1.24b * (1 - 16.10%))
Current Ratio = 4.18 (Total Current Assets 6.29b / Total Current Liabilities 1.51b)
Debt / Equity = 0.07 (Debt 700.0m / totalStockholderEquity, last fiscal year 10.00b)
Debt / EBITDA = -1.41 (Net Debt -2.35b / EBITDA 1.66b)
Debt / FCF = -2.32 (Net Debt -2.35b / FCF TTM 1.01b)
Total Stockholder Equity = 10.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.45% (Net Income 1.36b / Total Assets 13.06b)
RoE = 13.57% (Net Income TTM 1.36b / Total Stockholder Equity 10.05b)
RoCE = 11.61% (EBIT 1.24b / Capital Employed (Equity 10.05b + L.T.Debt 597.7m))
RoIC = 9.59% (NOPAT 1.04b / Invested Capital 10.82b)
WACC = 9.76% (E(48.41b)/V(49.11b) * Re(9.87%) + D(700.0m)/V(49.11b) * Rd(2.83%) * (1-Tc(0.16)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.76%
[DCF Debug] Terminal Value 66.25% ; FCFE base≈821.2m ; Y1≈623.1m ; Y5≈380.6m
Fair Price DCF = 9.16 (DCF Value 5.38b / Shares Outstanding 587.1m; 5y FCF grow -28.62% → 3.0% )
EPS Correlation: 28.69 | EPS CAGR: 1.68% | SUE: 4.0 | # QB: 5
Revenue Correlation: 61.40 | Revenue CAGR: 5.28% | SUE: 0.31 | # QB: 0

Additional Sources for EW Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle